CA3117682A1 — Formulations containing deuterated domperidone
Assigned to Cindome Pharma Inc · Expires 2020-04-30 · 6y expired
What this patent protects
The disclosure provides pharmaceutical formulations comprising d4-domperidone of the formula (I): (I) or a pharmaceutically acceptable salt thereof. The formulations also contain (i)a glyceryl stearate, and a medium chain triglyceride; or (ii) a stearoyl polyoxyl glyceride, a non…
USPTO Abstract
The disclosure provides pharmaceutical formulations comprising d4-domperidone of the formula (I): (I) or a pharmaceutically acceptable salt thereof. The formulations also contain (i)a glyceryl stearate, and a medium chain triglyceride; or (ii) a stearoyl polyoxyl glyceride, a nonionic poly(ethylene oxide) polymer, and a medium chain triglyceride; or (iii) a nonionic poly(ethylene oxide) polymer, and a polyethylene glycol. The disclosure also provides methods for treating a disorder that is gastroparesis, nausea apart from gastroparesis, vomiting apart from gastroparesis, nausea associated with gastroparesis, vomiting associated with gastroparesis, gastroesophageal reflux disease, insufficient lactation, or a combination thereof in a patient, comprising administering to the patient a formulation described herein. In some aspects, the disorder is gastroparesis. In other aspects, the disorder is gastroesophageal reflux disease. In further aspects, the disorder is insufficient lactation.
Drugs covered by this patent
- Aveed (TESTOSTERONE UNDECANOATE) · Marius
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.